ArticleCancer research2020
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance
Open access · bronzeAbstract readCase Reports
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 59 citations in OpenAlex.
- Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice.Signal transduction and targeted therapy · 2026Review
- Article
- TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations.Communications medicine · 2026Article
- Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945.NPJ precision oncology · 2025Article
- Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.International journal of molecular sciences · 2025Review
- Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation.Genes & diseases · 2025Article
- Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.Nature communications · 2025Article
- ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.Cancer research · 2024Article
- A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition.NPJ precision oncology · 2024Article
- Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse.Cold Spring Harbor perspectives in medicine · 2024Review
- The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Nature genetics · 2024Article
- Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.Frontiers in immunology · 2024Review
- Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.Current oncology (Toronto, Ont.) · 2023Review
- Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.Cell communication and signaling : CCS · 2023Review
- Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present).Pharmaceuticals (Basel, Switzerland) · 2023Review
- Acquired L718V/Annals of translational medicine · 2023Article
- Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR.Cancer research · 2023Article
- Mathematical analysis identifies the optimal treatment strategy for epidermal growth factor receptor-mutated non-small cell lung cancer.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 4 countries.
Jacqueline H StarrettDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Alexis A GuernetDiscovery Biology, Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge, United Kingdom.
Maria Emanuela CuomoDiscovery Biology, Discovery Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge, United Kingdom.
Kamrine E PoelsDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; and Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-7220-2213
Iris K van Alderwerelt van RosenburghDepartment of Pharmacology, Yale School of Medicine, New Haven, Connecticut.
Amy NagelbergDepartment of Integrative Oncology, British Columbia Cancer and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Dylan FarnsworthDepartment of Integrative Oncology, British Columbia Cancer and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Kristin S PriceGuardant Health, Redwood City, California.
Hina KhanWarren Alpert Medical School, Brown University, Providence, Rhode Island; and Lifespan Cancer Institute, Providence, Rhode Island.
Kumar Dilip AshtekarDepartment of Pharmacology, Yale School of Medicine, New Haven, Connecticut.
Mmaserame GaefeleYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Deborah AyeniDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Tyler F StewartDepartment of Medicine (Section of Medical Oncology), Yale School of Medicine, New Haven, Connecticut.
Alexandra KuhlmannDepartment of Immunobiology, Yale School of Medicine, New Haven, Connecticut.
Susan M KaechNOMIS Center for Immunobiology and Microbial Pathogenesis, The Salk Institute, La Jolla, California.
Arun M UnniMeyer Cancer Center, Weill Cornell Medicine, New York, New York.
Robert HomerDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-2055-5885
William W LockwoodDepartment of Integrative Oncology, British Columbia Cancer and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Franziska MichorDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; and Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sarah B GoldbergYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Mark A LemmonDepartment of Pharmacology, Yale School of Medicine, New Haven, Connecticut.
Paul D SmithR&D Oncology, AstraZeneca, Cambridge, United Kingdom.
Darren A E CrossOncology Business Unit, AstraZeneca Cambridge, United Kingdom.
Katerina PolitiDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu.
Yale University · USYale Cancer Center · USAstraZeneca (Singapore) · SGBC Cancer Agency · CACornell University · USDana-Farber Cancer Institute · USGuardant (United States) · USHarvard University · USProvidence College · USSalk Institute for Biological Studies · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0MViral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Ye Zheng · 1985 to 2026
$82.8MYale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Shuangge Ma · 2015 to 2026
$31.1MUnderstanding EGF receptor activation by growth factors and oncogenic mutationsR01CA198164 · NCI · YALE UNIVERSITY · PI FERGUSON, KATHRYN M, LEMMON, MARK A · 2015 to 2024
$5.2MYale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6MINVESTIGATING ACQUIRED RESISTANCE TO FIRST-LINE OSIMERTINIB IN EGFR MUTANT MODELS OF LUNG ADENOCARCINOMAF31CA228268 · NCI · YALE UNIVERSITY · PI STARRETT, JACQUELINE HEALY · 2019 to 2020
$36kCIHR PJT-148725NCATS NIH HHS UL1 TR001863NCI NIH HHS F31 CA228268NCI NIH HHS P30 CA014195NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA198164NCI NIH HHS T32 CA193200
Abstract
Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging as the preferred first-line therapy for
Indexed as
AcrylamidesAdenocarcinomaAfatinibAllelesAniline CompoundsAnimalsAntineoplastic AgentsDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideFemaleHumansIndolesLung NeoplasmsMiceMiddle AgedAcrylamidesAfatinibAniline CompoundsAntineoplastic AgentsErbB ReceptorsErlotinib HydrochlorideIndolesosimertinibProtein Kinase InhibitorsPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.